Study of tilsotolimod in combination with ipilimumab in anti-PD-1 refractory advanced melanoma fails to meet primary endpoint

In the ILLUMINATE-301 Phase III trial (n=481), the addition of intratumoral tilsotolimod (synthetic Toll-like receptor 9 agonist) to ipilimumab did not improve the objective response rate (8.8% v 8.6% ipilimumab alone). The study will continue to evaluate overall survival.

Biospace Inc.